Analysts Set Lantheus Holdings, Inc. (NASDAQ:LNTH) PT at $131.86

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have been assigned a consensus recommendation of “Buy” from the seven research firms that are presently covering the firm, Marketbeat reports. Seven analysts have rated the stock with a buy recommendation. The average 1 year price target among brokerages that have covered the stock in the last year is $131.86.

LNTH has been the subject of several analyst reports. StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. The Goldman Sachs Group initiated coverage on Lantheus in a research note on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective for the company. JMP Securities restated a “market outperform” rating and issued a $112.00 target price on shares of Lantheus in a research note on Tuesday, January 14th. Finally, Truist Financial reiterated a “buy” rating and set a $120.00 price target (down previously from $135.00) on shares of Lantheus in a research report on Friday, November 8th.

Lantheus Trading Down 2.0 %

Shares of NASDAQ:LNTH opened at $86.91 on Friday. The company has a 50 day moving average of $92.02 and a 200 day moving average of $98.46. The stock has a market cap of $6.04 billion, a P/E ratio of 14.46 and a beta of 0.44. Lantheus has a 12 month low of $54.69 and a 12 month high of $126.89.

Insider Buying and Selling

In other Lantheus news, Director James H. Thrall sold 1,000 shares of the company’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the sale, the director now directly owns 33,207 shares in the company, valued at $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 1.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Lantheus

Hedge funds and other institutional investors have recently modified their holdings of the stock. Wilmington Savings Fund Society FSB purchased a new position in Lantheus in the 3rd quarter worth approximately $25,000. Kestra Investment Management LLC bought a new position in shares of Lantheus in the fourth quarter worth approximately $27,000. Signaturefd LLC increased its stake in shares of Lantheus by 40.5% in the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after buying an additional 92 shares during the period. UMB Bank n.a. raised its holdings in Lantheus by 42.1% during the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after buying an additional 126 shares during the last quarter. Finally, Kathleen S. Wright Associates Inc. purchased a new stake in Lantheus during the 3rd quarter valued at $51,000. Institutional investors own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.